Enact Holdings, Inc. (ACT)
$
35.4
-0.25 (-0.71%)
Key metrics
Financial statements
Free cash flow per share
4.7796
Market cap
5.3 Billion
Price to sales ratio
4.3855
Debt to equity
0
Current ratio
0
Income quality
1.0474
Average inventory
0
ROE
0.1387
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Enact Holdings, Inc. operates as a private mortgage insurance company in the United States, specializing in writing and assuming residential mortgage guaranty insurance. The company focuses on offering private mortgage insurance products that primarily insure prime-based, individually underwritten residential mortgage loans, alongside contract underwriting services for mortgage lenders. With a commitment to efficiency, the gross profit ratio is 1.00 reflecting the effectiveness of the company’s production and sales operations. In managing its financial obligations, the company incurred an interest expense of $51,157,000.00 which underscores its debt servicing responsibilities. The income before tax ratio stands at 0.73 indicating a robust pre-tax margin. Furthermore, the company incurred an income tax expense of $189,993,000.00 which highlights its tax obligations. Operationally, Enact Holdings reported selling, general, and administrative expenses of -$113,318,000.00 reflecting the underlying costs associated with its overhead. In the investment landscape, Enact Holdings presents an attractive opportunity as the stock is affordable at $35.65 making it suitable for budget-conscious investors. The stock also shows a low average trading volume of 487,763.00 which indicates a level of lower market activity that may appeal to certain investors. With a mid-range market capitalization of $5,312,336,400.00 the company has established itself as a steady performer in a competitive environment. Enact Holdings is recognized as a key player in the Insurance - Specialty industry, significantly contributing to the overall market landscape. Furthermore, it operates within the Financial Services sector, consistently driving innovation and growth while maintaining its commitment to its core business of mortgage insurance.
Is Enact Holdings, Inc. (ACT) a good investment?
Investing in Enact Holdings, Inc. (ACT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Enact Holdings, Inc. (ACT)'s stock forecast?
Analysts predict Enact Holdings, Inc. stock to fluctuate between $29.37 (low) and $37.56 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Enact Holdings, Inc.'s market capitalization?
As of 2025-05-30, Enact Holdings, Inc.'s market cap is $5,312,336,400, based on 150,066,000 outstanding shares.
How does Enact Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Enact Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Enact Holdings, Inc. pay dividends?
Enact Holdings, Inc. pays dividends. The current dividend yield is 2.09%, with a payout of $0.21 per share.
How can I buy Enact Holdings, Inc. (ACT) stock?
To buy Enact Holdings, Inc. (ACT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACT. Place an order (Market, Limit, etc.).
What is the best time to invest in Enact Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Enact Holdings, Inc. perform in the last earnings report?
Revenue: $1,201,774,000 | EPS: $4.40 | Growth: 6.28%.
Where can I find Enact Holdings, Inc.'s investor relations reports?
Visit https://www.enactmi.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Enact Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Enact Holdings, Inc. stock?
All-time high: $37.56 (2025-05-02) | All-time low: $18.76 (2021-12-17).
What are the key trends affecting Enact Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
- ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction) , establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM
globenewswire.com
LONDON, Ontario, May 13, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc . (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced that it has entered into an agreement effective May 12th, 2025 (the “Agreement”) with Generation IACP Inc. (“Generation”) to provide market making services in accordance with Canadian Securities Exchange (CSE) policies.
prnewswire.com
- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy - Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK , May 6, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (NCT06768905). Initial clinical data from this trial is expected in the second half of 2025.
zacks.com
Stocks like ATKR, ACT, POOL and AWK recently announced dividend hikes.
seekingalpha.com
Enact Holdings, Inc. (NASDAQ:ACT ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Daniel Kohl - Vice President of Investor Relations Rohit Gupta - President and Chief Executive Officer Dean Mitchell - Chief Financial Officer Conference Call Participants Mihir Bhatia - Bank of America Merrill Lynch Douglas Harter - UBS Richard Shane - JPMorgan Chase & Co. Bose George - Keefe, Bruyette, & Woods, Inc. Operator Hello, and welcome to Enact's First Quarter Earnings Call. Please be advised that today's conference is being recorded.
zacks.com
Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.10 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.04 per share a year ago.
businesswire.com
MACON, Ga.--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, showcases its latest zero- and ultra-low emission commercial vehicle platforms at the upcoming 2025 Advanced Clean Transportation (ACT) Expo, North America's largest advanced transportation technology event. The company presents both its groundbreaking electric step van and propane-powered stripped chassis at the industry event from April 28-30, 2025, at the Anaheim Conventio.
zacks.com
Enact Holdings (ACT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
accessnewswire.com
ANAHEIM, CA / ACCESS Newswire / April 16, 2025 / Phoenix Motor Inc. dba PhoenixEV (NASDAQ:PEV), a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, is excited to announce its participation in the Advanced Clean Transportation (ACT) Expo, taking place from April 28 to May 1 at the Anaheim Convention Center. This prestigious event brings together industry leaders, innovators, and key stakeholders dedicated to advancing transportation solutions that prioritize sustainability and environmental responsibility.
globenewswire.com
RALEIGH, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its first quarter earnings release after the market closes on April 30, 2025. Enact will host a conference call to review first quarter 2025 financial results on May 1, 2025 at 8:00 a.m. (ET).
See all news
